BOARD OF DIRECTORS
Paula Skjefte, MBA, Executive Chair and CEO (see management page for bio).
Igor Efimov, PhD, Director and Chairman, Scientific Advisory Board, is the Alisann and Terry Collins Professor and Chair, Department of Biomedical Engineering at George Washington University. He obtained his Ph.D. in Biophysics and Biomedical Engineering, at the Moscow Institute of Physics and Technology in 1992, and his M.Sc., at the Moscow Institute of Physics and Technology, 1986. Prior to joining Washington University Biomedical Engineering School in 2004, he was a professor at Case Western Reserve for four years. He also held positions at the Cleveland Clinic Foundation, the University of Pittsburgh's School of Medicine and the Institute of Biological Physics in Puschino, Russia. Professor Efimov investigates bioelectric mechanisms of cardiac normal conduction and arrhythmia and has developed novel anti-arrhythmia therapies, including low-energy defibrillation therapy. Using molecular biology, tissue engineering and multimodal imaging techniques, the Efimov lab works to engineer the pacemaker and conduction system of the heart. Professor Efimov serves as Chief Scientific Advisor and Chairperson of the Cardialen Scientific Advisory Board.
Warren Watson, MSEE, Director, most recently Executive Chairman of the Board of Directors for Cameron Health, Inc. Prior to joining Cameron Health, he spent more than 33 years within Cardiac Rhythm Management organization at Medtronic, Inc., including several significant technical and commercial leadership roles. Mr. Watson spent eight years as the Vice President of Research and Development for Medtronic’s Cardiac Rhythm Management business as well as leading Medtronic’s Corporate R&D Council. Prior to that role, Mr. Watson served as General Manager of multiple Medtronic businesses and was the first Vice President of Marketing for Medtronic’s Tachyarrhythmia Business. Mr. Watson serves on the Board of Directors for Nuax, Inc., Gillette Children’s Specialty Healthcare, Citizens Independent Bank of St. Louis Park and Kinship of Greater Minneapolis. He previously served on the Board of Directors of CardioMems, Inc., Excigen, Inc., Endocardial Solutions, Inc., Survivalink, Inc. and the Continua Consortium. Mr. Watson received a Master’s of Science in Electrical Engineering from the University Of Minnesota Institute Of Technology.
Brian Beutner, JD, Investor Director, recently CEO of mPay Gateway, a venture-banked healthcare software company that has developed financial products and services for healthcare’s payment environment. He has led mPay Gateway from a development stage company, through fundraising rounds, to a profitable operating business. Prior to mPay Gateway, he spent seven years at UnitedHealth Group. He first served as General Counsel of UnitedHealthcare and then founded UnitedHealth Group’s consumer finance business, chartered Exante Bank (now OptumHealth Bank), and served as its Chair for three years. Prior to UnitedHealth Group he was an executive at Jostens, Inc, serving as General Counsel and Corporate Secretary. Brian began his career in the private practice of law, advising clients on a variety of financing and M&A transactions. Mr. Beutner received a Master’s in Business Administration from the Wharton School of the University of Pennsylvania and a JD from the University of Michigan Law School.
Eric Gulve, PhD, Investor Director, is President of BioGenerator, a private non-profit that provides pre-seed/seed funding and commercialization support for life science companies in the St. Louis area. Eric joined BioGenerator in 2007 to expand outreach to universities, increase the technologies reviewed, drive technical aspects of due diligence, and leverage his industry experience in shepherding technologies to commercial feasibility. His experience in the pharmaceutical industry in drug discovery research and licensing includes cardiovascular research at G.D. Searle, Pharmacia and Pfizer. Dr. Gulve received a B.A. in Chemistry from Occidental College and a Ph.D. in Physiology from Harvard University. He served as a post doctoral fellow and on the research faculty at Washington University School of Medicine.
Robert Calcaterra, DSc, Investor Director, is a principal of Startup Midwest Management LLC. Until 2008, he was President and CEO of the Nidus Center for Scientific Enterprise, a non-profit plant and life sciences incubator, where he worked with over 20 client companies and helped raise more than $140 million in capital. Previously, he had been founder, President and CEO of the Arizona Technology Incubator, the Boulder Technology Incubator, and held engineering positions with Monsanto, Coors, and Amoco. He also taught graduate courses in entrepreneurship at the University of Colorado, Arizona State University, and Washington University. Bob Calcaterra earned bachelor and master degrees in chemical engineering from the University of Nebraska and a doctorate in engineering from Washington University. He later completed Harvard University's Industrial Research Institute Executive Management Seminar.
William Schmidt is a general managing partner in the Cultivation Capital Life Science Fund. He has over 20 years of experience in the medical device, healthcare IT and pharmaceutical sectors, and was a founding partner of LDM Group, recently sold to Physician Desk Reference (PDR, LLC). Prior to LDM, he held various executive leadership positions, most notably at United States Surgical Corporation (now Covidien) and Catalina Marketing’s Health Resource division. Bill also participates as a mentor in the Capital Innovators accelerator program and is an angel investor himself. He holds an electrical engineering degree from the University of Wisconsin.